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In the last decade, many efforts have been made to characterize anatomic changes of head and neck
organs at risk (OARs) and the dosimetric consequences during radiotherapy. This review was undertaken
to provide an overview of the magnitude and frequency of these effects, and to investigate whether we
could ﬁnd criteria to identify head and neck cancer patients who may beneﬁt from adaptive radiotherapy
(ART). Possible relationships between anatomic and dosimetric changes and outcome were explicitly
considered. A literature search according to PRISMA guidelines was performed in MEDLINE and
EMBASE for studies concerning anatomic or dosimetric changes of head and neck OARs during radiother-
apy. Fifty-one eligible studies were found. The majority of papers reported on parotid gland (PG) ana-
tomic and dosimetric changes. In some patients, PG mean dose differences between planning CT and
repeat CT scans up to 10 Gy were reported. In other studies, only minor dosimetric effects (i.e. <1 Gy dif-
ference in PG mean dose) were observed as a result of signiﬁcant anatomic changes. Only a few studies
reported on the clinical relevance of anatomic and dosimetric changes in terms of complications or qual-
ity of life. Numerous potential selection criteria for anatomic and dosimetric changes during radiotherapy
were found and listed. The heterogeneity between studies prevented unambiguous conclusions on how
to identify patients who may beneﬁt from ART in head and neck cancer. Potential pre-treatment selection
criteria identiﬁed from this review include tumour location (nasopharyngeal carcinoma), age, body mass
index, planned dose to the parotid glands, the initial parotid gland volume, and the overlap volume of the
parotid glands with the target volume. These criteria should be further explored in well-designed and
well-powered prospective studies, in which possible relationships between anatomic and dosimetric
changes and outcome need to be established.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 115 (2015) 285–294
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Radiotherapy is a commonly applied treatment modality in
head and neck cancer patients. Intensity modulated radiotherapy
treatment plans with steep dose gradients are currently considered
standard. These treatment plans are constructed on planning CT
images, acquired prior to the start of radiotherapy. To account for
patient positioning errors relative to these planning CT images,
position veriﬁcation procedures are generally applied. However,
because of different patient postures and anatomic changes during
the course of radiotherapy, the dose actually given to the patient
can deviate from the planned dose [1]. These dose differences
may lead to underdosage to target volumes and/or overdosage to
organs at risk (OARs) [2].Radiation-induced complications have a signiﬁcant adverse
impact on health-related quality of life [3]. Hence, it is important
to monitor radiation doses to OARs during treatment. This is partic-
ularly salient in the head and neck area, where OARs are in close
proximity to target volumes. However, at present, veriﬁcation of
the dose actually given to the patient is not considered routine clin-
ical practice. Adaptive radiotherapy (ART) could be applied to
reduce dose to OARs and eventually to improve quality of life [4–
8]. ART is a formal approach to correct for daily tumour and normal
tissue variations through streamlined online or ofﬂine modiﬁcation
of original target volumes and plans [9,10]. Implementation of ART
is challenging both from clinical and logistic points of view and gen-
erally requires many resources. Clear guidelines are needed on the
timing of rescanning and replanning, and an increasing amount of
data needs to be acquainted, handled, transferred and stored. It is
unlikely that every patientwill beneﬁt fromART and therefore tools
286 Changes of head and neck organs at risk during RTto select patients who are expected to beneﬁt most from plan adap-
tation during treatment become increasingly important [11].
In previous studies, it was shown that anatomic changes cause
more dose deviations in OARs than in target volumes [12–15].
Clinical target volume (CTV) coverage is usually more robust to
changes because of the use of the planning target volume (PTV) con-
cept, while planning volumes at risk (PRV) margins are generally
applied for the spinal cord andbrain stem, but are not commonprac-
tice for all OARs. Only 13% of the studies in this review reported PRV
margins around the spinal cordand/or thebrainstem[4,5,11,16–18],
and 4% of the studies reported on PRVmargins for all OARs [5,16]. In
addition, position veriﬁcation mainly focuses on correcting for
set-up errors of targets, and for that reason might lead to increased
doses to distant OARs. Therefore, it is expected that the largest gain
of ART would be the monitoring and reduction of the dose to OARs.
For a strategic selection of patients who may beneﬁt from ART,
identiﬁcation of selection criteria that are associated with dosimet-
ric changes and resulting complications is necessary. Patient selec-
tion for ART can be realized by selection prior to treatment, i.e.
based on pre-treatment characteristics, and by selection during
treatment based on geometric and/or dosimetric changes early in
treatment, either by non-imaging related factors (e.g. weight loss)
or by imaging related factors (e.g. density changes).
Castadot et al. [19] have summarized the results of seven stud-
ies reporting on anatomic modiﬁcations of head and neck target
volumes and OARs during radiotherapy in 2010. The authors con-
cluded that radiotherapy induces major volumetric and positional
changes in CTVs and OARs during treatment. Parotid glands tend to
shrink and to shift medially towards the high dose region, poten-
tially jeopardizing parotid sparing [19]. Not all of these studies
reported to what extent these anatomic changes actually translate
into dosimetric changes. Furthermore, no unambiguous effect of
anatomic changes on dose has been found. Since 2010, the amount
of studies reporting on anatomic and dosimetric changes has
increased dramatically.
The main objective of this review was to evaluate the current
literature on anatomic and dosimetric changes of head and neck
OARs during radiotherapy. Furthermore, implications of these
changes for the rate and severity of complications and quality ofLiterature database searching 
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Fig. 1. PRISMA ﬂow diagramlife were reported. In addition, we tried to identify selection crite-
ria for changes during radiotherapy and recommended on the con-
duction of further studies on this subject. Results of this review
could provide useful information for the development of strategies
for patient selection in ART.
Methods
We performed a literature search in MEDLINE and EMBASE
according to PRISMA guidelines [20] using the following keywords:
((synonyms for anatomic changes) OR (synonyms for dosimetric
changes)) AND (synonyms for organs at risk) AND (synonyms for
head and neck radiotherapy). The search was completed by March
1, 2015.
In addition, reference lists of papers were screened in order to
retrieve additional relevant papers. Both prospective and retro-
spective studies published in journals part of the Thomson
Reuters journal citation reports were included. Studies in lan-
guages other than English, and studies only available in abstract
form were excluded from this review.
Studies had to fulﬁl the following eligibility criteria to be
selected for this review:
 report on anatomic and/or dosimetric changes of adult head and
neck organs at risk during the course of photon radiotherapy,
and
 at least ten patients included.
We present overviews of anatomic changes, dosimetric
changes, and report potential selection criteria of either one. In
addition, we report on studies describing the effects of anatomic
and dosimetric changes during radiotherapy on side effects and
quality of life. The results are presented by volume changes in per-
centages and dose changes in Gray in order to make comparisons
across studies easier to interpret. Associations are presented in ﬁve
ways; by the Pearson correlation coefﬁcient (R), the coefﬁcient of
determination (R2), the Spearman’s rank correlation coefﬁcient
(q), linear regression analysis (r or r2), and by the odds ratio
(OR), according to the study methodology.Records excluded because of 
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1. Ahn et al. [31] fx 11 (mean)
2. Bhide et al. [34] end of tx
3. Capelle et al. [36] fx 15
4. Castadot et al. [11] fx 20-25
5. Chen et al. [15] end of tx
6. Cheng et al. [16] fx 25
7. Duma et al. [38] fx 25
8. Duma et al. [13] fx 16 (median)
9. Fung et al. [41] fx 30-35
10. Hansen et al. [2] fx 29 ± 9
11. Height et al. [42] fx 20-25
12. Ho et al. [43] fx 25-30
13. Jensen et al. [44] fx 5-35
14. Lee et al. [46] end of tx
15. Marzi et al. [48] end of tx
16. Nishi et al. [4] fx 10-20
17. Robar et al. [17] end of tx
18. Wang et al. [59] fx 18
19. Wu et al. [12] fx 25-30
20. Zhao et al. [6] fx <20
21. Ajaniet al. [32] fx 25-30
22. Barker et al. [33] end of tx
23. Broggi et al. [35] end of tx
24. Lu et al. [47] fx 20
25. Riche et al. [53] fx 30-35
26. Sanguine et al. [62] fx 16(median)
27. Vasquez et al. [57] fx 23
28. Wang et al. [60] end of tx
29. Cozzolino et al. [66] fx 25
30. Hunter et al. [65] end of tx
31. Castelli et al. [63] fx 25-30
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Fig. 2. (A) Parotid volume loss vs. patient’s weight loss (22 studies), (B) parotid volume loss vs. planned parotid mean dose (20 studies), (C) parotid mean dose increase
(repeat CT – plan CT) vs. weight loss (16 studies), and (D) parotid mean dose increase (repeat CT – plan CT) vs. parotid volume loss (23 studies) during radiotherapy. The size
of the data points is proportional to the number of patients included in the study (minimum 10, maximum 87 patients). fx = fraction, tx = treatment. Time point: time of the
repeat scan analysed.
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Literature search
Fig. 1 presents the outcome of the search strategy. Fifty-two
potentially eligible records were found in MEDLINE and EMBASE,
and forty-four additional papers were extracted from reference
lists. We excluded twenty-eight records as they were conference
abstracts, two studies because only the abstract was available
[21,22], and two papers because their journal was not part of the
Thomson Reuters journal citation reports [23,24]. Furthermore,
three papers were excluded as they were general reviews on image
guided radiotherapy (IGRT) and ART [9,19,25]. Eventually,
sixty-one full text articles were assessed for eligibility. Five of these
papers did not meet the eligibility criteria since they reported on
other subjects and ﬁve papers included less than ten patients
[26–30]. Hence a ﬁnal number of ﬁfty-one studies could be
included in the analyses for this review [2,4–7,11–18,31–68].
Reported organs at risk
In the ﬁfty-one original studies at least one of the following
organs at risk was included in the analysis: the parotid gland
(PG), submandibular gland, spinal cord, spinal canal, brainstem,
mandible, oral cavity, larynx, pharyngeal constrictor muscles, ster-
nocleidomastoid muscles, masticatory muscles, masseter muscles,
medial pterygoid muscles, thyroid gland, optic chiasm, optic nerve,
eyeball and lens.
Timing and frequency of imaging during radiation treatment
OARswere assessed on different timepoints during radiotherapy
(tenth fraction to end of treatment, see also Fig. 2, Table S1–S3)mainly by cone beam CT (CBCT), helical repeat CT and megavolt-
age CT (MVCT), but also by in-room CT [14,17,44,51] and MR
imaging [52]. Two studies applied repeat MR imaging in addition
to the repeat CT scans [15,16]. In most studies, the
re-delineation of OARs was performed manually or automatically
using deformable image registration (DIR) with visual inspection
and manual corrections if needed. The frequency of imaging
varied between studies. Most of the studies reported on multiple
time points during radiotherapy. Fourteen studies performed at
least weekly repeat imaging [7,12,17,18,37,43–46,51,53,62,63,65
]. Three of these studies had daily MVCT imaging at their dis-
posal [18,45,46], and one performed daily in-room CT imaging
[7]. If results of multiple time points were reported, anatomic
and dosimetric changes from the last time point were included
in this review.
The authors of the different studies reported a variety of time
points during treatment that could be optimal for re-scanning
and re-planning. There are several indications that anatomic
changes are more pronounced in the ﬁrst half of treatment, and
therefore repeated imaging and replanning should be performed
in this ﬁrst time period [34,60,62,65].Anatomic and dosimetric changes
Twenty-six papers described both anatomic and dosimetric
changes during the course of radiation [2,4,6,11–13,15–17,31,34,
36,38,39,41–44,46,48,54,59,61,63,65,66]. Two studies reported on
dosimetric changes without referring to anatomic changes
[18,51]. Twenty studies described the relationship between
several parameters and anatomic and/or dosimetric changes [4,7,
11,31–33,35,36,40,43,46,48,57,59,60,62–65,68] (Table 1 and 2).
288 Changes of head and neck organs at risk during RTTwelve studies reported on the association between anatomic
and dosimetric changes with complications and quality of life
[5–7,48,50,54,55,61,63,65,67,68] (Table 3). In two of these
studies, a signiﬁcant reduction of side effects was found when
replanning was performed vs. no replanning [5,6]. The ﬁndings of
speciﬁc changes during radiotherapy and the corresponding
correlations and associations are summarized per organ in the next
paragraphs.Table 1
Studies reporting on parameters associated with anatomic or dosimetric changes of parotid
shown. Results of Spearman correlation are denoted with q, Pearson correlation with R, li
Study # Pts Parameter Endpoi
Anatomic endpoints
Ahn et al. [31] 23 Weight loss PG vol
Ajani et al. [32] 13 Weight loss PG vol
PG DmeanP 31 Gy vs. PG Dmean < 31 Gy
Barker et al. [33] 14 Weight loss PG cen
Broggi et al. [35]* 87 Weight loss PG vol
DBody thickness (cc)
OVP
PG V40
Overall treatment time
Initial PG volume
PG Dmean
PG V40 PG vol
DBody thickness (%)
Fiorino et al. [40] 84 PG density decrease PG vol
Ho et al. [43] 10 Weight loss PG vol
Reali et al. [64] 10 PG Dmean PG vol
Sanguineti et al. [62] 85 Weight loss PG vol
PG Dmean
Age
Sanguineti et al. [68] 85 Body mass index PG vol
PG Dmean
Schwartz et al. [7] 24 Weight loss PG vol
Vasquez-Osorio et al.
[57]
10 PG Dmean PG vol
Wang et al. [60] 82 PG Dmean PG vol
SMG Dmean SMG v
Wang et al. [59] 15 Weight loss PG vol
Dosimetric endpoints
Ahn et al. [31] 23 Cochlea vector increase PG D50
Mandible vector increase
Reduction of lateral neck diameter at
mandibular joint
Reduction of lateral neck diameter at C1–C5
Parotid volume decrease
Weight loss
Anatomic isocentre AP PG D50
Mandible vector, AP, SI
Reduction of lateral neck diameter at C2–C3
Capelle et al. [36]* 20 Reduction of neck diameter mid-PTV level Combin
Castadot et al. [11] 10 Contralateral PG shrinkage slope (cc/day) Contra
increas
Castelli et al. [63] 15 CTV70 shrinkage PG me
Reduction of neck diameter
Hunter et al. [65] 18 PG mean dose difference ﬁrst fraction (Gy) PG me
treatm
Lee et al. [46] 10 PG COM distance decrease PG me
Weight loss
Marzi et al. [48] 15 DGTV (cm3) PG me
Wang et al. [59] 15 Weight loss PG me
Pts = patients, PG = parotid gland, ipsi = ipsilateral, contra = contralateral, n.r. = not repo
gland and lymphnodal tumour, COM = centre of mass, OR = odds ratio (95% conﬁdence
* Only the strongest associations were listed.Parotid gland
The majority of the studies included anatomic and/or dosimet-
ric changes of the parotid glands (PGs). This interest for PG changes
during radiotherapy can be explained by the fact that radiation
dose to the PGs was associated with reduced saliva production
[69] and xerostomia [70,71].
When all studies were taken into account, the average volume
decrease of the PGs during radiotherapy was 26 ± 11% (note:glands during the course of radiotherapy. Only statistically signiﬁcant correlations are
near regression analysis by r or r2 and odds ratio by OR.
nt Correlation/association p value
ume loss R = 0.52–0.67 n.r.
ume loss q = 0.66 p < 0.01
tre of mass shift q = 0.931, Spearman two-tailed
correlation
p < 0.01
ume loss (cc) OR = 0.845 (0.78–0.92), univariable
analysis
p = 0.0001
OR = 0.181 (0.078–0.422), ‘‘ p = 0.0001
OR = 1.191 (1.086–1.306), ‘‘ p = 0.0002
OR = 1.038 (1.011–1.066), ‘‘ p = 0.006
OR = 1.059 (1.018–1.100), ‘‘ p = 0.004
OR = 1.100 (1.056–1.158),
multivariable analysis
p = 0.0002
OR = 1.059 (1.003–1.118), ‘‘ p = 0.038
ume loss (%) OR = 1.034 (1.0075–1.061),
multivariable analysis
p = 0.012
OR = 0.863 (0.809–0.921), ‘‘ p < 0.00001
ume loss q = 0.23 p = 0.003
ume loss q = 0.83 p < 0.0001
ume loss r2 = 0.31, 0.41 (left, right PG) p < 0.001
ume loss OR = 1.160 (1.04–1.29),
multivariable analysis
p = 0.007
OR = 1.080 (1.01–1.17), ‘‘ p = 0.038
OR = 0.960 (0.93–0.99), ‘‘ p = 0.033
ume loss q = 0.234 p = 0.031
q = 0.258 p = 0.017
ume loss n.r. p = 0.04
ume loss r = 0.68 p < 0.001
ume loss r = 0.41 p < 0.001
olume loss r = 0.39 p < 0.001
ume loss q = 0.93, 0.85 (left, right PG) p < 0.001
% increase R = 0.41 n.r.
R = 0.42 n.r.
R = 0.22–0.39 n.r.
R = 0.17–0.28 n.r.
R = 0.22 n.r.
R = 0.30–0.35 n.r.
% overdose (D50% > 26 Gy) n.r. p = 0.002
n.r. p = 0.001–
0.006
n.r. p = 0.07–
0.08
ed PGmean dose increase q = 0.64 p = 0.002
lateral PG mean dose
e
0.62, correlation measure n.r. p = 0.006
an dose increase n.r., Linear mixed effect model p < 0.01
an dose difference (end of
ent)
q = 0.92 p < 0.001
an dose increase r2 = 0.88 n.r.
r2 = 0.58 n.r.
an dose increase r2 = 0.43, Stepwise multiple
regression
p = 0.015
an dose increase q = 0.85 p < 0.001
rted, AP = anterior–posterior, SI = superior–inferior, OVP = overlap volume parotid
intervals).
Table 2
Studies reporting on parameters associated with contour reduction (anatomic endpoints) and dosimetric changes of spinal cord and mandible (dosimetric endpoints) during the
course of radiotherapy. Only statistically signiﬁcant correlations are shown. Results of Spearman correlation were denoted with q, Pearson correlation with R.
Study # Pts Parameter Endpoint Correlation/association p value
Anatomic endpoints
Barker et al. [33] 14 Weight loss External contour volume reduction
at level of C2 and at base of skull
q = 0.917 and 0.936,
respectively,
Spearman two-tailed
correlation
p < 0.01
Fiorino et al.
[40]
84 PG density decrease Absolute neck thickness reduction
at C2 level
q = 0.27 p = 0.0005
Dosimetric endpoints
Ahn et al. [31] 23 Mandible vector increase Spinal cord Dmax increase R = 0.27 n.r.
Reduction of lateral neck diameter at
mandibular joint
R = 0.30 n.r.
Reduction of lateral neck diameter
at C4–C6
R = 0.17–0.27 n.r.
Reduction of lateral neck diameter
at mid tumor level
R = 0.18 n.r.
DGTV (cm3) Mandible V60 increase R = 0.26 n.r.
Cochlea/incisive roll, pitch, RL, AP Spinal cord Dmax overdose
(Dmax > 45 Gy)
n.r. p = 0.024–
0.054
Mandible roll, yaw n.r. p = 0.034
C3–C7 vector n.r. p = 0.002–
0.043
C2–6 pitch n.r. p = 0.001–
0.005
C2–C5 AP n.r. p = 0.001
Lordosis n.r. p = 0.001
Anatomic isocentre vector RL Mandible overdose n.r. p = 0.001–
0.002
Cochlea/incisive AP, RL, roll n.r. p = 0.013–
0.039
Mandible vector/yaw/roll/pitch n.r. p = 0.004–
0.028
Capelle et al.
[36]*
20 Reduction of lateral neck diameter
at the level of the thyroid notch
Spinal cord Dmax increase q = 0.73 p < 0.0001
Normal tissue V50 increase q = 0.71 p < 0.0001
Castadot et al.
[11]
10 GTV shrinkage slope (cc/day) Spinal cord D2% increase 0.75, correlation measure n.r. p = 0.001
Nishi et al. [4] 20 DGTVp (cm3) Spinal cord D2% increase q = 0.91 n.r.
Wang et al. [59] 15 Weight loss Spinal cord Dmax increase q = 0.652 p < 0.05
Pts = patients, PG = parotid gland, n.r. = not reported, AP = anterior–posterior, SI = superior–inferior, RL = right-left, GTVp = the volume of primary gross tumour.
* Only the most predictive parameters were listed.
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Table S1). Some studies presented the PG shrinkage rate per treat-
ment day or treatment week [15,33,37]. Sanguineti et al. [62] stud-
ied weekly CT scans of eighty-ﬁve patients and concluded that the
PG shrinkage is not linear (PGs shrunk most during the ﬁrst half of
treatment).
Thirty-eight papers reported on PG anatomic changes [2,4,6,7,
9,12,13,15–17,31–45,47,48,50,53,56,57,59,60,62–66]. The most
common reported anatomic changes were volume loss (Table S1)
and medial shifts of the PGs [17,32–34,37,42,44,45,48,51,57,59,64
]. Jensen et al. [44] found a medial, cranial, and dorsal shift of the
PG centre of mass from its original position. In general, a medial
shift was observed of the medial and lateral aspects of both PGs
[4,17,32,48,57]. Vasquez-Osorio et al. [57] reported on shape and
position changes of six sub-regions of the PG. The medial transla-
tion of the inferior region of the irradiated PGs was similar to that
of the lateral region (3 ± 4 mm). Fiorino et al. [40] and Belli et al.
[67] found reduced PG densities during IMRT.
Twenty-four papers reported on dosimetric changes of the PGs
[2,4,6,11–13,15–18,31,34,36,38,41–44,46,48,51,59,65,66]. On aver-
age, the PG mean dose increased with 2.2 ± 2.6 Gy as compared to
the dose calculated on the planning CT at baseline. Not all papers
reportedonabsolutedosevalues. The studies that reported thehigh-
est dose increase consisted of (a majority of) (naso)pharyngeal car-
cinoma patients [4,6,15,16,34,46,58]. The largest PG dose increase
was found by Chen et al. [15] and Cheng et al. [16] (on average anincrease of the mean dose of 10.4 Gy in the sixth week of radiother-
apy, and an increase of themedian dose of 7.8 Gy at the twenty ﬁfth
fraction, respectively). Both prospective studies included stage III–
IV nasopharyngeal carcinoma patients.
Factors correlating with parotid gland volume loss and parotid mean
dose increase. Eighteen studies reported on factors that correlated
signiﬁcantly with PG anatomic and/or dosimetric changes
(Table 1). The most frequently reported factors were weight loss,
PG dose and PG volume loss. All data available are presented in
Fig. 2. On average, no clear relation between these factors and
changes was found. The strongest association found was between
PG dose and PG volume loss; three of the larger studies (more than
eighty patients included) reported a signiﬁcant correlation of PG
dose with PG volume loss [35,60,62]. Still, a large variety of volume
loss was observed between studies (Fig. 2B).
Details of correlations on individual study level can be found in
the Supplementary Material. Table 1 includes all factors that
demonstrated signiﬁcant correlations (p < 0.05) with correspond-
ing correlation/association measures.
Anatomic and dosimetric changes of the parotid gland and
outcome. Signiﬁcant associations between PG volume change and
the occurrence of complications were found in ﬁve studies
[7,48,55,67,68] (Table 3). In general, more PG shrinkage was asso-
ciated with higher complication rates [48,67]. On the contrary,
Table 3
Studies reporting on side effects or quality of life in relation to anatomic or dosimetric alterations during radiotherapy. Only signiﬁcant associations are shown. Results of
Spearman correlation were denoted with q, linear regression analysis with r or r2 and odds ratio by OR.
Study # Pts Parameter Endpoint Association p-value
Anatomic parameters
Belli et al.
[67]
46 DPG rate (mm3/day) Mean xerostomia (CTC v3.0) score (treatment
course)P 1.57
OR = 0.10 (0.03–0.93) p = 0.02
DDensity rate PG (HU/day) OR = 0.15 (0.99–1.00),
Logistic univariable analysis
p = 0.04
Marzi et al.
[48]
15 DGTV (cm3) DNTCP grade 3 or higher RTOG toxicity
12 months after RT*
r2 = 0.609, stepwise multiple
regression
p = 0.074
DPG (%) p = 0.010
Nishimura
et al. [50]
33 Initial volume of PG DPG (%) Xerostomia score at 3–4 months q = n.r.
q = n.r.
p = 0.040
p = 0.186
Teshima et al.
[55]
20 PG volume ratio post-RT/pre-
RT (%)
Saliva reduction amount (g) q = 0.79, Spearman rank
correlation and Fisher exact test
p < 0.01
Sanguineti
et al. [68]
85 DPG (%) mid treatment Time to reduction of the acute xerostomia grade
(CTCAE v3.0) (from Pgrade 2 to grade 1)
HR = 1.034 (1.004–1.064),
multivariable analysis
p = 0.024
Schwartz
et al. [7]
24 PG shrinkage (%) end of
treatment
Duration of PEG tube use q = n.r., two-tailed
nonparametric Spearman
p = 0.025
Senkus-
Konefka
et al. [54]
33 Lateral dimension changes at
beam axis
Degree of mucositis r = n.r. p = 0.017
You et al. [61] 31 Weight loss >5% and/or
decrease of neck diameter >10%
Acute xerostomia 6grade 1 vs. grade 2 n.r. p = 0.02, t-test
Dosimetric parameters
Castelli et al.
[63]
15 IMRT replanning vs. no
replanning in over-irradiated PG
group
Xerostomia risk* n.r. p < 0.01
Hunter et al.
[65]
18 PG Dmean (planned) Stimulated selective PG salivary output 6 months
post-treatment (cc/min)
q = 0.55 p < 0.0007
PG Dmean (delivered) q = 0.57 p < 0.0004
Yang et al. [5] 129 IMRT replanning vs. no
replanning
Global quality of life** n.r. p = 0.012, ANOVA
Speech problems n.r. p = 0.000
Trouble with social contact n.r. p = 0.000
Teeth n.r. p = 0.031
Opening mouth n.r. p = 0.000
Dry mouth n.r. p = 0.000
Sticky saliva n.r. p = 0.015
Zhao et al. [6] 33 TxN2,3 replanning vs. no
replanning
Mucosa n.r. p = 0.05, Mann
Whitney
Wilcoxon
Xerostomia n.r. p = 0.04
* Hypothetical difference in NTCP, assessed by LKB model.
** EORTC QLQ-C30 scales role functioning, social functioning, dyspnoea, appetite loss, constipation and diarrhoea all statistically signiﬁcant. PG = parotid gland,
Pts = patients, n.r. = not reported, OR = odds ratio (95% conﬁdence intervals).
290 Changes of head and neck organs at risk during RTSanguineti et al. [68] observed that the patients who received
mean doses over 35.7 Gy to the PG developed more
physician-reported GR2+ xerostomia if the shrinkage of the com-
bined volume of parotid glands was lower than 19.6%. Nishimura
et al. [50] found out that the patients with initially small parotid
glands (638.8 ml) had signiﬁcantly more severe xerostomia three
to four months after the start of IMRT than patients with initially
larger parotid glands (p = 0.040), while the correlation between
the shrinkage of PG and the grade of xerostomia was not signiﬁcant
(p = 0.186) (Table 3). Belli et al. found that apart from volume
decrease, also early density decrease was associated with signiﬁ-
cantly higher acute xerostomia scores (Table 3). Weight loss >5%
and/or decrease of neck diameter >10% was associated with higher
xerostomia scores in the study of You et al. [61]. Hunter et al. con-
cluded that dosimetric changes were small relative to the standard
deviations of the dose and saliva ﬂow data [65].
Yang et al. [5] studied global quality of life in addition to the dif-
ferent side effects for IMRT replanning vs. no replanning, and
reported better quality of life and less side effects for the IMRT
replanning group (Table 3).
Submandibular glands
In contrast to the parotid glands, information on anatomic and
dosimetric changes of the submandibular glands is scarce. On aver-
age, a submandibular gland volume reduction of 22% (15–32%) was
found [37,57,60]. Wang et al. [60] found a signiﬁcant correlation
between the planned submandibular gland dose (r = 0.389,p < 0.001) and submandibular gland volume reduction, while no
such correlations were found by others [57]. Irradiated sub-
mandibular glands tend to move superiorly, in particular the cau-
dal and lateral sub-regions with displacements of on average 3–
4 mm [57]. Similar results were found by Castadot et al. [11].
These authors also observed superior as well as medial shifts of
the submandibular glands. In this study, the mean approximated
actually delivered doses to the submandibular glands increased
compared with the planned doses (52.8 vs. 51.9 Gy) (Table S3).
Brainstem and spinal cord
A number of authors reported on changes in maximum doses or
D1% to the brainstem [2,6,15,16,18,31,34,41–43,59] and the spinal
cord [2,6,11,13,15,16,18,31,34,36,41–43,59,66] during the course
of treatment (results are listed in Table S3). Zhao et al. [6] found
the highest dose increase in D1% of the spinal cord and the brain-
stem of on average 0.20 and 0.09 Gy per fraction, which would
result in an accumulated excess dose of 5.6 and 2.5 Gy, respec-
tively, for the entire treatment course. Cheng et al. [16] reported
that if no replanning was performed, for 11% and 16% of the
patients the tolerance dose of 54 Gy for the maximum dose to
the brainstem was exceeded after 30 and 50 Gy, respectively, and
for 11% of the patients the maximum dose to the spinal cord was
higher than 45 Gy after both 30 and 50 Gy.
Factors correlating with brainstem and spinal cord dose increase. A
number of variables correlated signiﬁcantly with an increase in
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in GTV volume, weight loss, change in neck diameter at the level
of the thyroid notch and a few other anatomic, CT related variables
(Table 2).
Other organs at risk
The results of studies regarding anatomic and/or dosimetric
changes of the larynx, masseter muscle, medial pterygoid, pharyn-
geal constrictor muscles, sternocleidomastoid muscles, mastica-
tory muscles, thyroid gland, mandible, submandibular glands,
oral cavity, optic chiasm, optic nerve, eyeball, lens and cochlea
are listed in Tables S2 and S3, respectively [2,11,13,16,18,31,49,5
2,53,66]. Clear swelling of the larynx and pharyngeal constrictor
muscles was found by Ricchetti et al. [53] at week seven of radio-
therapy. Swelling of the larynx was also reported by Cozzolino
et al. [66], ﬁve weeks after the start of radiotherapy. Popovtzer
et al. [52] observed a thickness change of +111% in parts of the pha-
ryngeal constrictors that received more than 50 Gy, three months
post chemoradiation. However, the thickness and volume of the
sternocleidomastoid muscles decreased [52,53].
In most publications, only small changes in the mean dose
(<1 Gy) to organs at risk during the course of radiotherapy have
been reported [11,13,18] (Table S3). Dosimetric changes to e.g.
the mandible are more often caused by head rotation instead of
anatomic changes [12]. In contrast, a rather large increase in max-
imum and D1% was found by Cheng et al. [16] for some organs after
30 and 50 Gy, with the largest dose increase for the optic nerves
after 50 Gy (Dmax increase from 48.5 ± 4.5 to 56.3 ± 5.0 Gy (ipsilat-
eral) and from 26.7 ± 16.1 to 36.9 ± 20.8 Gy (contralateral)
(mean ± SD)) (Table S3). This means that for individual cases, the
maximum dose to the optic nerve could have been >60 Gy if no
replanning was performed, with a markedly increased risk of tox-
icity as a consequence [72].Discussion
This is the ﬁrst review that focused on anatomic and dosimetric
changes of head and neck organs at risk during the course of radio-
therapy and on the correlation of these changes with side effects.
In total, ﬁfty-one papers on this subject were identiﬁed according
to the PRISMA methodology [20].
The parotid gland was the most studied OAR and showed the
largest volume changes during radiotherapy (26% average volume
decrease). The dosimetric consequences of PG shrinkage varied
widely, with on average a PG mean dose increase of 2.2 ± 2.7 Gy.
Only a few studies investigating volume changes of the sub-
mandibular glands were found. This could be explained by their
location, encompassed by neck lymph node level IB and in close
proximity to the frequently irradiated neck lymph node level II.
This complicates their sparing and results in high initial sub-
mandibular gland doses, possibly less sensitive for dosimetric
variations.Introduction of adaptive radiotherapy
ART for head and neck patients is currently subject to many
studies. Theoretically, ART could be performed by adapting treat-
ment plans to the actual patient anatomy on a daily basis. Yan
and Liang showed in a retrospective planning study of nineteen
patients that weekly adaptive inverse planning optimization
already improved the dose distribution of head and neck cancer
treatment signiﬁcantly [8]. Chen et al. [73] suggested from their
retrospective study that for appropriately selected patients the
theoretical beneﬁts i.e. improved dose distributions of ART may
be associated with actual clinical advantages. The authors alsoconcluded that routine replanning is probably not necessary. This
is conﬁrmed by our own experience, based on weekly repeat CT
scans, showing that in less than 20% of all head and neck patients
replanning was needed because of target underdosage or OAR
overdosage, usually during the ﬁrst three weeks of treatment (per-
sonal communication).
Only limited data are published so far on the effect of dosimet-
ric changes on the occurrence of side effects or quality of life (cur-
rent review, Table 3). The optimal frequency and utilization, as
well as the ultimate clinical impact of ART still remain to be deter-
mined [9,14,25]. There are several indications that anatomic
changes are more pronounced in the ﬁrst half of treatment, and
therefore repeated imaging and replanning should be performed
in this ﬁrst time period [34,60,62]. Schwartz et al. [14] conducted
a prospective clinical trial, and concluded that properly timed
replanning could result in dosimetric improvement, but that the
clinical impact of ART remains to be conﬁrmed. Dawson and
Sharpe [25] stated that increased precision and accuracy of radio-
therapy are expected to augment tumour control and reduce the
incidence and severity of toxic effects after radiotherapy. On the
other hand, they mentioned that the desire for sub-millimetre
technical precision needs to be balanced with risk of chasing only
modest clinical gains and the possibility of imposing an unaccept-
able workload on radiotherapy planning, delivery, and review pro-
cesses. There are limited resources at most radiotherapy
departments, and identiﬁcation of patients that beneﬁt from ART
would restrict the workload tremendously and thus would be more
cost-effective. Results of future prospective clinical trials linking
anatomic and dosimetric changes to outcome are needed to con-
ﬁrm the clinical impact of ART.Application of selection criteria for ART
The potential selection criteria for PG volume loss identiﬁed in
the current review that may improve the selection of patients for
ART prior to treatment were tumour location (nasopharyngeal car-
cinoma), age, body mass index, planned dose to the parotid glands,
the initial parotid gland volume, and the overlap volume of the PG
with lymph node metastases. PG volume loss is in this case pre-
sumed to result in higher complication rates [48,55,67] (Table 3).
This could be due to an increase in PG dose, or to a direct relation-
ship between PG volume and complications [67,68]. For the major-
ity of patients, PG volume loss resulted in an increase of the mean
dose to the PGs (Fig. 2D). However, we could not conﬁrm a clear
association between volume loss and mean dose increase
(Fig. 2D). This can be explained by the fact that the treatment plan
and consequential dose distribution depend on many factors such
as the location of the boost volume.
Apart from selection of patients prior to treatment, selection
during treatment could be performed, based on either detected
changes or by parameters related to these changes. Weight loss,
change in body thickness, reduction of lateral neck diameter, PG
volume decrease, PG density decrease, distance between PG cen-
tres of mass and GTV volume decrease turned out to be potential
selection criteria for either PG volume loss, increase of the PG dose
and/or differences in the degree of side effects (Tables 1 and 3).
Considering the other OARs, weight loss and GTV volume decrease
during radiotherapy positively correlated with the maximum dose
to the spinal cord (Table 2), and lateral dimension changes at beam
axis correlated well with the degree of mucositis [54].
The difﬁculty with most of the potential selection criteria found
in this review to select patients for ART is that although statistically
signiﬁcant associations were found with anatomic and/or dosimet-
ric endpoints, thesewere generallyweak (Tables 1 and2).Moreover,
most potential selection criteria resulted from correlation tests,
although regression analysis is more suitable to investigate the
292 Changes of head and neck organs at risk during RTpredictive power. Furthermore, some authors reported Pearson cor-
relation coefﬁcients, although normal distribution of the data and
the linear relationship between variables was not proven. If a
non-linear but monotonic relationship between variables is
observed, the Spearman correlation should be used.
To enable proper selection of patients for re-planning, multi-
variable prediction models are needed, derived from sufﬁciently
powered prospective study populations. Most studies in this
review consisted of limited patient populations and were therefore
not suitable for model development. The performance of such
models should be sufﬁcient to identify patients that need ART with
high sensitivity and speciﬁcity.Bias in individual studies
It is likely that the large heterogeneity in results as depicted in
Fig. 2 can be explained by differences between study designs, such
as different patient and tumour characteristics (localization, stag-
ing), differences in timing of repeated imaging, treatment (combi-
nation with surgery/chemotherapy), treatment technique (IMRT or
tomotherapy), margins, speciﬁc settings of the radiotherapy treat-
ment planning, and patients’ nutritional status.
Another problem in the comparison of the results of the differ-
ent studies is that different types of analysis were used, and results
were reported in different quantities (e.g. volume changes in % or
cm3, dose changes in % of prescribed dose or in Gy). Also, individual
patient data and standard deviations of the differences were often
lacking. These aforementioned differences in study design and the
variation in methods of analysis and reported quantities are one of
the most common problems in systematic reviews of prognostic
studies [74]. It is therefore not possible to perform a
meta-analysis, but it is a strong argument in favour of systematic
reviews [74]. On the individual study level, random allocation of
patients is seldom performed. Often, detailed study inclusion crite-
ria are lacking, and some of the studies are retrospective, most
likely selecting patients that suffer most from anatomic and dosi-
metric changes during treatment. Two studies from China investi-
gated the effect of replanning on quality of life [5,6] (Table 3). In
both studies, signiﬁcant lower incidences of side effects were
found in the replanning group with respect to the no replanning
group. Conversely, patients were not randomly allocated to the dif-
ferent treatment groups, and therefore differences in these speciﬁc
studies might be explained by other factors such as differences in
socioeconomic status between the two populations [75].Inaccuracies in the calculation of dosimetric changes
Two factors of inaccuracy in the ART chain that inﬂuence the
accuracy of the calculation of dose on repeat imaging are contour-
ing variability and the dose recalculation procedure on (MV)CBCT.
Earlier studies showed that the coefﬁcients of variance for contour-
ing OARs varied between 12% and 16% [76] resulting in dose differ-
ences of on average 3.5 Gy [77]. Automatic contouring on MVCBCT
was found to be comparable to inter-observer uncertainty in delin-
eating parotid glands on CT [78]. Morin et al. [79] showed that dose
calculation on MVCBCT could be performed within a 3% / 3 mm
accuracy. In kV-CBCT imaging the dosimetric error depends on
the HU adjustment technique and imaging artefacts. For the spinal
cord Dmax the error could be >5% [80]. Some dose differences found
in this review are thus in the same order of magnitude as differ-
ences that could be introduced because of contouring variability
or dose calculation inaccuracy. For instance given a mean dose of
30 Gy to the PG, a deviation of 3% would result in a deviation of
0.9 Gy. We should therefore pay attention to select the most accu-
rate and reproducible segmentation and dose calculation proce-
dures to most accurately predict actual given doses.Conclusions
Despite the relatively large number of studies published so far,
the heterogeneity between studies prevented unambiguous con-
clusions on how to select patients for adaptive radiotherapy in
head and neck cancer. Still, a number of potential selection criteria
for anatomic and dosimetric changes were identiﬁed that could be
included in well-designed and well-powered studies on anatomic
and dosimetric changes during radiotherapy, including tumour
location (nasopharyngeal carcinoma), age, body mass index,
planned dose to the parotid glands, the initial parotid gland vol-
ume, and the overlap volume of the parotid glands with the target
volume. There is a need for larger prospective studies including
assessment of anatomic and dosimetric changes, and to identify
possible relationships between these changes and outcome.
Moreover, we hope to draw attention to the paucity of good quality
data on this subject so far, and therewith improve the quality of
future research.Conﬂict of interest
None.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2015.05.
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